PD-1 Inhibitors

11 registered clinical trials studyying PD-1 Inhibitors — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Electro-Acupuncture in Lung cancER : EALER Study NCT07337096	Guangzhou University of Traditional Chinese Medicine	N/A
Recruiting	Electroacupuncture Combined With PD-1 Inhibitor for ECOG2 Advanced NSCLC NCT07239661	Kong Fanming	N/A
Recruiting	Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLC NCT07086300	Kong Fanming	N/A
Active Not Recruiting	Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer NCT07359040	Peking University People's Hospital	—
Not Yet Recruiting	Combination of SFRT, PD-L1 Inhibitor, and Anti-VEGF in Advanced Hepatocellular Carcinoma NCT06708650	Guiping People's Hospital	N/A
Unknown	IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC) NCT06078657	The First Affiliated Hospital of Zhengzhou University	Phase 2
Unknown	Single-center, Prospective Cohort Study of PD-1 Inhibitors on Clinical Outcomes of Carotid Plaques in Tumor Pa NCT05549336	Second Affiliated Hospital, School of Medicine, Zhejiang University	—
Completed	HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416) NCT06631326	First Hospital of China Medical University	—
Completed	Stereotactic Body Radiotherapy Combined With PD-1 Blockers for Locally Advanced or Locally Recurrent Pancreati NCT06195254	Peking University Third Hospital	—
Unknown	Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer. NCT04490421	Fuzhou General Hospital	Phase 3
Unknown	PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phas NCT05520814	Sichuan Cancer Hospital and Research Institute	Phase 2